J
John C. Reid
Researcher at Merck & Co.
Publications - 21
Citations - 1094
John C. Reid is an academic researcher from Merck & Co.. The author has contributed to research in topics: Binding site & Cyclin-dependent kinase 9. The author has an hindex of 16, co-authored 21 publications receiving 939 citations. Previous affiliations of John C. Reid include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Restoring Methicillin-Resistant Staphylococcus aureus Susceptibility to β-Lactam Antibiotics
Christopher M. Tan,Alex G. Therien,Jun Lu,Sang Ho Lee,Alexandre Caron,Charles Gill,Christian Lebeau-Jacob,Liliana L. Benton-Perdomo,João M. Monteiro,Pedro M. Pereira,Nathaniel L. Elsen,Jin Wu,Kathleen Deschamps,Mihai Petcu,Simon Wong,Etienne Daigneault,Susanne Kramer,Lianzhu Liang,Eugene Maxwell,David Claveau,John P. Vaillancourt,Kathryn Skorey,John Tam,Hao Wang,Timothy C. Meredith,Susan Sillaots,Lisa Wang-Jarantow,Yeeman K. Ramtohul,Eric Langlois,John C. Reid,Gopal Parthasarathy,Sujata Sharma,Anastasia Baryshnikova,Kevin J. Lumb,Mariana G. Pinho,Stephen M. Soisson,Terry Roemer +36 more
TL;DR: A Staphylococcus aureus antisense knockdown strategy is adapted to genetically identify the cell division Z ring components—FtsA, FtsZ, and FtsW—as β-lactam susceptibility determinants of methicillin-resistant S. aureUS to support a target-based approach to develop synergistic drug combinations to combat MRSA with improved efficacy and reduced potential for drug resistance.
Journal ArticleDOI
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
Thomas J. Tucker,John T. Sisko,Tynebor Robert M,Theresa M. Williams,Peter J. Felock,Jessica A. Flynn,Ming-Tain Lai,Yuexia Liang,Georgia B. McGaughey,Meiquing Liu,Michael W. Miller,Gregory Moyer,Vandna Munshi,Rebecca Perlow-Poehnelt,Sridhar Prasad,John C. Reid,Rosa I. Sanchez,Maricel Torrent,Joseph P. Vacca,Bang-Lin Wan,Youwei Yan +20 more
TL;DR: A series of novel, highly potent NNRTIs that possess broad spectrum antiviral activity and good pharmacokinetic profiles are designed and synthesized to address a critical issue with the emergence of clinical resistance.
Journal ArticleDOI
Mechanism of action of the cell-division inhibitor PC190723: modulation of FtsZ assembly cooperativity.
Nathaniel L. Elsen,Jun Lu,Gopal Parthasarathy,John C. Reid,Sujata Sharma,Stephen M. Soisson,Kevin J. Lumb +6 more
TL;DR: It is demonstrated that PC190723 negatively modulates Staphylococcus aureus FtsZ polymerization cooperativity as reflected in polymerization at lower concentrations without a defined critical concentration.
Journal ArticleDOI
Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors
Hua-Poo Su,Youwei Yan,G. Sridhar Prasad,Robert F. Smith,Christopher L. Daniels,Pravien Abeywickrema,John C. Reid,H. Marie Loughran,Maria Kornienko,Sujata Sharma,Jay A. Grobler,Bei Xu,V V Sardana,Timothy J. Allison,Peter D. Williams,Paul L. Darke,Daria J. Hazuda,Sanjeev Munshi +17 more
TL;DR: These structures provide a means for structurally guided design of novel RNase H inhibitors, and one of the naphthyridinone-based compounds was found to bind at a second site close to the polymerase active site and non-nucleoside/nucleotide inhibitor sites in a metal-independent manner.
Journal ArticleDOI
Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity.
Sanjeev Munshi,Maria Kornienko,Dawn L. Hall,John C. Reid,Lloyd Waxman,Steven M. Stirdivant,Paul L. Darke,Lawrence C. Kuo +7 more
TL;DR: The x-ray structure of the unactivated kinase domain of insulin-like growth factor-1 receptor (IGFRK-0P) is reported here at 2.7 Å resolution, suggesting that the juxtamembrane region of one molecule could come into close proximity to the active site of the other.